Ethinylestradiol/gestodene - Bayer HealthCare Pharmaceuticals/Wyeth

Drug Profile

Ethinylestradiol/gestodene - Bayer HealthCare Pharmaceuticals/Wyeth

Alternative Names: Arianna; Ethinylestradiol/gestodene (Mirelle); Meliane Light; Melodene; Melodia; Microgeste; Minesse; Mirelle

Latest Information Update: 09 Feb 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer Schering Pharma
  • Class Alkylated estrogenic steroids; Norpregnatrienes; Norpregnenes
  • Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Pregnancy

Most Recent Events

  • 09 Feb 2015 Launched for Contraception/Pregnancy (Prevention) in Israel, South Africa and Thailand (PO) prior to February 2015
  • 16 Oct 2009 Wyeth has been acquired by Pfizer
  • 29 Dec 2006 Schering AG is now called Bayer Schering Pharma AG
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top